Christine Marie Utter - Mar 29, 2023 Form 4 Insider Report for PTC THERAPEUTICS, INC. (PTCT)

Role
SVP, FINANCE & CAO
Signature
/s/ Avraham S. Adler, Attorney-in-Fact
Stock symbol
PTCT
Transactions as of
Mar 29, 2023
Transactions value $
-$224,044
Form type
4
Date filed
3/31/2023, 04:21 PM
Previous filing
Mar 29, 2023
Next filing
Apr 25, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PTCT Common Stock Options Exercise $190K +4.69K +12.32% $40.45 42.7K Mar 29, 2023 Direct F1
transaction PTCT Common Stock Sale -$155K -3.25K -7.6% $47.80 39.5K Mar 29, 2023 Direct F1, F2
transaction PTCT Common Stock Sale -$68.8K -1.44K -3.65% $47.78 38.1K Mar 29, 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PTCT Stock Option (Right to Buy) Options Exercise -$190K -4.69K -100% $40.45 0 Mar 29, 2023 Common Stock 4.69K $40.45 Direct F1, F3
holding PTCT Stock Option (Right to Buy) 17.8K Mar 29, 2023 Common Stock 17.8K $51.00 Direct F3
holding PTCT Stock Option (Right to Buy) 4.32K Mar 29, 2023 Common Stock 4.32K $33.02 Direct F3
holding PTCT Stock Option (Right to Buy) 371 Mar 29, 2023 Common Stock 371 $33.02 Direct F3
holding PTCT Stock Option (Right to Buy) 23.8K Mar 29, 2023 Common Stock 23.8K $51.16 Direct F4
holding PTCT Stock Option (Right to Buy) 50.8K Mar 29, 2023 Common Stock 50.8K $66.49 Direct F5
holding PTCT Stock Option (Right to Buy) 43.5K Mar 29, 2023 Common Stock 43.5K $38.10 Direct F6
holding PTCT Stock Option (Right to Buy) 32.5K Mar 29, 2023 Common Stock 32.5K $39.42 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on February 24, 2023.
F2 This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $47.50 to $48.285 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F3 Currently exercisable.
F4 This option was granted on January 29, 2020, and vests over four years, with 25% of the shares underlying the option vesting on January 29, 2021, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 29, 2021.
F5 Represents an option award of 33,250 options and an option award of 17,500 options. These option awards were each granted on January 6, 2021, and each vests over four years, with 25% of the shares underlying the option vesting on January 6, 2022, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 6, 2022.
F6 This option was granted on January 7, 2022, and vests over four years, with 25% of the shares underlying the option vesting on January 7, 2023, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 7, 2023.
F7 This option was granted on January 5, 2023, and vests over four years, with 25% of the shares underlying the option vesting on January 5, 2024, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 5, 2024.